Venom immunotherapy protocols in the pediatric population: how to choose?

Venom immunotherapy (VIT) is, to date, the only available long-term treatment for HVA. Recommendations provided by scientific societies may also be applied to childhood, though no international pediatric-specific documents have been published for the management of HVA. In the last years, despite the huge amount of literature on VIT being produced, most of the studies evaluate only adult populations. Some of these also include children, but often, pediatric data are not separately analyzed. In the most recent years, some scientific groups have specifically studied the indications, safety, and efficacy of VIT in childhood. Nonetheless, it is still difficult to compare those studies since they analyze different VIT regimens in heterogeneous populations. In this review, we aim to dissert and evaluate relevant articles with specific data on VIT in pediatric ages.